Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

173.02B

Market cap173.02B

Price-Earnings ratio

20.11

Price-Earnings ratio20.11

Dividend yield

2.32%

Dividend yield2.32%

Average volume

7.30M

Average volume7.30M

High today

$140.34

High today$140.34

Low today

$137.00

Low today$137.00

Open price

$137.71

Open price$137.71

Volume

7.88M

Volume7.88M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$93.37

52 Week low$93.37

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $139.96, giving the company a market capitalization of 173.02B. It carries a P/E multiple of 20.11 and pays a dividend yield of 2.3%.

During the trading session on 2026-04-01, Gilead Sciences(GILD) shares reached a daily high of $140.34 and a low of $137.00. At a current price of $139.96, the stock is +2.2% higher than the low and still -0.3% under the high.

Trading activity shows a volume of 7.88M, compared to an average daily volume of 7.3M.

The stock's 52-week range extends from a low of $93.37 to a high of $157.29.

GILD News

TipRanks 19h

Galapagos, Gilead enter pact to collaborate on T cell engager therapies

Galapagos (GLPG) announced that it has entered into a binding agreement with Gilead (GILD) in connection with Gilead’s definitive agreement to acquire all of th...

Simply Wall St 4d

Gilead’s Arcellx Deal Deepens Oncology Focus And Reshapes Investor Risk Profile

Gilead Sciences (NasdaqGS:GILD) agreed to acquire Arcellx in a US$7.8b deal. The transaction gives Gilead full rights to anito cel, a CAR T cell therapy for mu...

Nasdaq 5d

Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?

Gilead Sciences, Inc. GILD is accelerating its external innovation strategy through targeted acquisitions to bolster its pipeline and diversify beyond its domin...

Analyst ratings

75%

of 32 ratings

Buy

75%

Hold

21.9%

Sell

3.1%

More GILD News

Simply Wall St 5d

A Look At Gilead Sciences Valuation After Recent Share Price Weakness

Advertisement Recent share performance and business scale Gilead Sciences (GILD) has traded weaker over the past month, with a roughly 7% decline and about a...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.